LSTA

#4421
Lisata Therapeutics, Inc. Common Stock
4.53 USD
-9.22%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
4.53
4.53
Faixa anual
1.81
5.06
Mudança diária
-9.22%
Mudança mensal
-10.12%
Mudança em 6 meses
+92.77%
Mudança anual
+126.50%
Fechamento anterior
4.99
Abrir
4.53
Bid
Ask
Mínimo
4.53
High
4.53
Volume
2
Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
Demonstração de resultados Balanço patrimonial Fluxo de caixa
Valor 20202021202220232024 TTM

Lisata Therapeutics Inc

Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.

Notícias